NCT07472972Recruiting
Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)
Source: ClinicalTrials.gov · Last updated 16 Mar 2026
Brief summary (registry, in English)
The INTeRCePT 2 study aims to develop a predictive assay to determine which patients with B cell lymphoma are most likely to respond to CAR T cell therapy. This assay combines five components for longitudinal profiling of each patient. The goal of the trial is that the assay can be completed (feasibility). This comprehensive assay integrates five key components including circulating tumor DNA (CAPPseq), inflammation markers from peripheral blood tests (InflaMIX), PET CT imaging parameters, immune cell profiles (flow cytometry), and performance status (ECOG). Ultimately, this tool could improve treatment selection, and guide more personalized therapy decisions for lymphoma patients receiving CAR T cells.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 14 Nov 2025
- Start date
- 20 Jun 2025
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- University of Zurich
- Diseases
- Childhood cancers
- NCT number
- NCT07472972
What you commit to
- Study type: Observational
- Planned participants: 50
- From 20 Jun 2025 to the primary completion date, 1 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any condition, which precludes initiation of CD19-redirected CAR T cell therapy (e.g. breast feeding, pregnancy, infections, etc.) as judged by the treating physician
- Any coexisting medical or psychological condition that would preclude participation in the required study procedures, as judged by the treating physician
Other
- Unwillingness or inability to comply with the protocol
Who the study is looking for
- Written informed consent before registration and prior to any trial specific procedures
- Participants ≥ 18 years of age
- Diagnosis of relapse/refractory B-cell lymphoma according to WHO 2022 classification
- Measurable disease per response criteria specific to the disease e.g. per Lugano 2014 criteria
- Patients planned for CD19-redirected CAR T cell therapy according to clinical standard of care
- Patients who are willing to donate peripheral blood and biopsy material at indicated clinical visits
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universityhospital Zurich, Department of Medical Oncology and Hematology Coordinator of this site? Confirm its status | Zurich | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.